WHITE PAPER
From Regulated Prices to Prices Set in Tenders
Tendering landscape in Europe
Oct 31, 2022
Download

Tendering for medicines becomes an increasingly important part of the healthcare ecosystem, and is responsible for the purchasing of a cohort of medicines that are critical to long-term savings for payers (biosimilars), to patient outcomes (hospital tendered specialty medicines), and to public health (vaccine tenders). Despite the high formalization and complexity of the process, IQVIA estimates that tendering accounts for around 40% of drug purchases in Europe, and in many countries it can be 80% - 100% of drug purchases in the hospital channel.

IQVIA has undertaken this study to support the healthcare industry, and to provide greater clarity in this increasingly important segment of the market. The study covers the definitions, steps, and systems that govern the tendering system for the benefit of commercial stakeholders, and for the creators of tenders in Europe.

The findings of this report highlight the variability in the usage, type, and process of tendering. It showcases some of the best-in-class approaches, and provides a landscape for the tendering market in a time when commercial decision making is critical to success, as well as to the long-term sustainability of the healthcare system in Europe. This study describes the tendering market in the area of drugs understood as original medicines, biosimilars, generic medicines and vaccines.

Contact Us